DWDebbie Ann White

Debbie Ann White

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Debbie Ann White has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Ameena Goga

    Department of Paediatric Pulmonology Steve Biko Academic Hospital/University of Pretoria Pretoria South Africa

    1 shared publication
  • Anthony Marius Smith

    Affiliations National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa, Department of Medical Microbiology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa

    1 shared publication
  • Arshad Ismail

    Sequencing Core Facility, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; Department of Biochemistry and Microbiology, Faculty of Science, Engineering and Agriculture, University of Venda, Thohoyandou 0950, South Africa; Institute for Water and Wastewater Technology, Durban University of Technology, Durban 4000, South Africa

    1 shared publication
  • Brenda May Morrow

    Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa

    1 shared publication
  • Daynia Elizabeth Ballot

    Department of Pediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    1 shared publication
  • Heather Jessica Zar

    Department of Pediatrics and Child Health, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa

    1 shared publication

Latest Publications

  • Open Access

    Detection of the epidemic Pseudomonas aeruginosa AUST‐03 (ST242) strain in people with cystic fibrosis in South Africa

    by Thabo Hamiwe, Debbie A. White, Stanford Kwenda, Arshad Ismail, Susan Klugman, Lore Van Bruwaene, Ameena Goga, Marleen M. Kock, Anthony M. Smith, Marthie M. Ehlers

    Introduction: Pseudomonas aeruginosa AUST‐03 (ST242) has been reported to cause epidemics in people with CF (pwCF) from Australia and has been associated with multidrug resistance and increased morbidity and mortality. Here, we report an epidemic P. aeruginosa (AUST‐03) strain in South African pwCF detected at a public hospital and characterize the genomic antibiotic resistance determinants. Methods: The P. aeruginosa AUST‐03 (ST242) study isolates were analysed with whole genome sequencing using the Illumina NextSeq2000 platform. Raw sequencing reads were processed using the Jekesa pipeline and multilocus sequence typing and genomic antibiotic resistance characterization was performed using public databases. Genetic relatedness between the study isolates and global P. aeruginosa ST242 from public databases was determined using a maximum‐likelihood phylogenetic tree. Antibiotic susceptibility testing was performed using the disk diffusion and broth microdilution techniques. Results: A total of 11 P. aeruginosa AUST‐03 isolates were isolated from two children with CF. The majority (8/11) of these isolates were multidrug‐resistant (MDR) or extensively drug resistant; and the multidrug efflux pumps MexAB‐OprM, MexCD‐OprJ, MexEF‐OprN, and MexXY‐OprM were the most clinically relevant antibiotic resistance determinants and were detected in all of the isolates. The study isolates were the most closely related to a 2020 P. aeruginosa AUST‐03 (ST242) CF isolate from Russia. Conclusion: Epidemic MDR P. aeruginosa strains are present at South African public CF clinics and need to be considered when implementing segregation and infection control strategies to prevent possible spread and outbreaks.


  • Open Access

    A comparison between raw and predicted mortality in a paediatric intensive care unit in South Africa

    by Daynia Elizabeth Ballot, Tanusha Ramdin, Debbie Ann White, Jeffrey Lipman

    Paediatric intensive care resources are limited in sub-Saharan Africa. The mortality rate in a combined Paediatric/Neonatal Intensive Care Unit in Johannesburg, South Africa was almost double that in a dedicated paediatric intensive care unit in the same country. This study aimed to compare the raw mortality rate with that predicted with the Paediatric Index of Mortality (version 3), by doing a retrospective analysis of an existing database. A total of 530 patients admitted to the intensive care unit between 1 January 2015 and 31 December 2017 were included. The raw mortality rate was 27.1% and the predicted mortality rate was 27.0% (p = 0.971). Cardiac arrest during ICU admission (p < 0.001), non-reactive pupils (0.035), inotropic support (p < 0.001) and renal disease (p = 0.002) were all associated with an increased risk of mortality. These findings indicate that the high mortality rate is due to the severity of illness in the patients that are admitted. It also indicates that the quality of care delivered is acceptable.


  • Open Access

    Acute viral bronchiolitis in South Africa: Viral aetiology and clinical epidemiology

    by Debbie A White, Shabir A Madhi, Prakash A Jeena, Heather J Zar, Brenda M Morrow, Refiloe Masekela, Samuel Risenga, Robin J Green

    Bronchiolitis is a viral-induced lower respiratory tract infection that occurs predominantly in children <2 years of age, particularly infants. Many viruses have been proven or attributed to cause bronchiolitis, including and most commonly the respiratory syncytial virus (RSV) and rhinovirus. RSV is responsible for more severe disease and complications (including hospitalisation) in bronchiolitis patients. Whereas bronchiolitis is exclusively due to respiratory viral infections, with little evidence of bacterial co-infection, the former could nevertheless predispose to superimposed bacterial infections. Although data support an interaction between RSV and pneumococcal superimposed infections, it should be noted that this specifically refers to children who are hospitalised with RSV-associated pneumonia, and not to children with bronchiolitis or milder outpatient RSV-associated illness. As such, empiric antibiotic treatment against pneumococcus in children with RSV-associated pneumonia is only warranted in cases of hospitalisation and when the clinical syndrome is more in keeping with pneumonia than uncomplicated bronchiolitis. In South Africa, the peak in the RSV season varies only slightly by province, with onset in February, and lasting until June. The important implication of these new seasonality findings is that where prophylaxis is possible, as in the case of RSV, it should be commenced in January of each year.